The high plasma level of lipoprotein(a) [Lp(a)] is associated with higher morbidity and mortality of coronary heart disease. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. In contrast, the physiological function of the genetically highly determined Lp(a) is unknown. The metabolic fate of Lp(a) has also escaped our understanding. Due to numerous gaps in the knowledge about the Lp(a) therapeutic for influence of its plasma level is unresolved. There are few medications which have been shown to lower the plasma concentration of Lp(a), however since these drugs all have multiple other effects their use is not the choice of the therapy. A number of examinations suggest that elevated plasma low-density cholesterol (LDL) concentration is required for Lp(a) to contribute to atherosclerosis significantly. According to the results of intervention studies the best therapeutic option for high plasma Lp(a) level is to lower the plasma level of LDL.
|Translated title of the contribution||The role of lipoprotein(a) - The 'game' is not over|
|Number of pages||7|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Dec 1 1999|
ASJC Scopus subject areas